Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Neonatal adaptation in hypertensive pregnancy — A study of labetalol vs hydralazine treatment

Neonatal adaptation in hypertensive pregnancy — A study of labetalol vs hydralazine treatment Introduction Curriculum vitae RAGNHILD HJERTBERG, M.D., was graduated from Uppsala University in 1979 and qualified as a specialist in Obstetrics and Gynecology in 1988. Since 1982 she has worked at the Department of Obstetrics and Gynecology, Karolinska Hospital and Karolinska Institute, Stockholm, Sweden, and is a member of the staff since 1991. Hypertension in pregnancy affects about 5% of all pregnant women [6] in a Swedish population. In this group there is a high maternal and fetal morbidity. The policy regarding how, when, and with what antihypertensive drug these patients should be treated, has been a matter of debate [2, 21]. In Sweden, the most common drug to treat hypertension in pregnancy has been hydralazine until the 80s. In the last decade, betablockers and the combined alpha- and betablocker labetalol have come into increasing use [13]. Hydralazine is a mild vasodilator with a wide range of interindividual dose response [18]. It has a negative effect on uteroplacental circulation, especially when the patient does not respond with a prompt blood pressure reduction [19]. Labetalol is a non-selective betablocker and a post-synaptic alpha-1 blocking agent. It decreases systemic vascular resistance with little or no change in cardiac output. It has http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Perinatal Medicine de Gruyter

Neonatal adaptation in hypertensive pregnancy — A study of labetalol vs hydralazine treatment

Loading next page...
 
/lp/de-gruyter/neonatal-adaptation-in-hypertensive-pregnancy-a-study-of-labetalol-vs-upsfpju33P

References (13)

Publisher
de Gruyter
Copyright
Copyright © 2009 Walter de Gruyter
ISSN
0300-5577
eISSN
1619-3997
DOI
10.1515/jpme.1993.21.1.69
Publisher site
See Article on Publisher Site

Abstract

Introduction Curriculum vitae RAGNHILD HJERTBERG, M.D., was graduated from Uppsala University in 1979 and qualified as a specialist in Obstetrics and Gynecology in 1988. Since 1982 she has worked at the Department of Obstetrics and Gynecology, Karolinska Hospital and Karolinska Institute, Stockholm, Sweden, and is a member of the staff since 1991. Hypertension in pregnancy affects about 5% of all pregnant women [6] in a Swedish population. In this group there is a high maternal and fetal morbidity. The policy regarding how, when, and with what antihypertensive drug these patients should be treated, has been a matter of debate [2, 21]. In Sweden, the most common drug to treat hypertension in pregnancy has been hydralazine until the 80s. In the last decade, betablockers and the combined alpha- and betablocker labetalol have come into increasing use [13]. Hydralazine is a mild vasodilator with a wide range of interindividual dose response [18]. It has a negative effect on uteroplacental circulation, especially when the patient does not respond with a prompt blood pressure reduction [19]. Labetalol is a non-selective betablocker and a post-synaptic alpha-1 blocking agent. It decreases systemic vascular resistance with little or no change in cardiac output. It has

Journal

Journal of Perinatal Medicinede Gruyter

Published: Jan 1, 1993

There are no references for this article.